Raymond James raised the firm’s price target on Monopar Therapeutics (MNPR) to $142 from $80 and keeps a Strong Buy rating on the shares. The publication of peer-reviewed Letter to the Editor in the Journal of Hepatology corrected previous copper balance data for ALXN1840, the analyst tells investors in a research note. The firm thinks shares can continue to work well into 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer
- Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright
- Monopar Therapeutics price target raised to $85 from $60 at Chardan
- Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler
- Monopar Therapeutics Announces Underwriting Agreement for Stock Sale